Business
CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California
CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Nov. 27, 2018\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Nov. 27, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that Mr. Eyal Barad, CEO, will be presenting at the LD Micro Main Event. \nThe presentation will provide an overview of the company's mission and activities and provide insight into the path forward towards bringing a valuable and needed service to cancer patients, who are using cannabis.\nMr. Barad will also describe how the company plans on leveraging its technology to solidify partnerships which create long term value.\nMr. Barad is scheduled to speak on December 5th, from 12:00pm – 12:30pm PT. \n\"It is important for us to bring our story and present it to the investment community at this important event,\" said Mr. Barad. \"What differentiates us is our proprietary IP and our AI predictive platform based on our personalized approach to treating cancer and its side effects.\n\"We feel honored to be one of the few companies in the world to be government licensed to do cancer and cannabinoid research, and we're looking forward to sharing our recent advancements and current plans.\"\nThe LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel. It will feature 250 companies and will be attended by over 1,200 individuals.\nAbout Cannabics Pharmaceuticals  \nCannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By dev...